Phase II Study of Diclofenac Salvage in Patients Metastatic Non-Small Cell Lung Cancer with Early Signs of Progression on Single Agent PD(L)-1 Blockade
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs Cemiplimab (Primary) ; Diclofenac (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Jan 2025 New trial record